Sarcoma cancer vaccines and uses thereof
OwnerChristopher A. Klebanoff, Sandra D'Angeloinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides vaccine compositions comprising recombinant SS 18::SSX fusion peptide epitopes and at least one cancer-testis antigen (CTA) epitope, or nucleic acids (e.g., mRNA, cDNA) encoding the same, and methods for using the same to treat sarcoma (e.g., synovial sarcoma) in a subject in need thereof.
Claims40
A vaccine comprising a polypeptide comprising at least one SS18::SSX fusion junction epitope and an oligomer of at least one cancer-testis antigen (CTA) epitope, wherein the at least one SS18::SSX fusion junction sequence comprises the amino acid sequence of PQQRPYGYDQIMPKKPAEDE (SEQ ID NO:
- 1), optionally wherein the at least one SS18::SSX fusion junction epitope is operably linked to the oligomer.
A vaccine comprising a nucleic acid molecule encoding a polypeptide comprising at least one SS18::SSX fusion junction epitope and an oligomer of at least one cancer-testis antigen (CTA) epitope, wherein the at least one SS18::SSX fusion junction sequence comprises the amino acid sequence of PQQRPYGYDQIMPKKPAEDE (SEQ ID NO:
- 1), optionally wherein the at least one SS18::SSX fusion junction epitope is operably linked to the oligomer.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.